Beijing Hotgen Biotechnology co., Ltd., an enterprise located in the ZGC Medical Device Park, became the first IVD enterprise that have passed the examination of the Listing Committee of the Sci-tech Innovation Board of Shanghai Stock Exchange on the evening of July 30, 2019.

Hotgen is a high-tech biotechnology enterprise committed to the integration of new in vitro diagnostic technology platform and innovation. The company is positioned to provide full-scene applications of immune products, focusing on in vitro medical diagnosis and testing in the public safety field. Its products cover UPT (up-converting phosphor technology) POCT (point-of care test), chemiluminescence, hepatitis and liver cancer diagnosis and cancer-prevention physical examination, etc.

From 2016 to 2018, Hotgen’s corresponding operation revenue is 122, 142, 187 million yuan respectively, among which the net profit attributable to the parent company is 28.80, 30.07 and 48.19 million yuan. Notably, as a key part of operation income, its detection reagent business has been growing by more 85% during the past three years.

The ZGC Medical Device Park is dedicated to supporting and serving enterprises in the park, helping them go public on the Sci-tech Innovation Board and driving them to develop technology.